Evidence map›Paper›PMID 40589636›Full record

ArticleFrontiers in oncology2025

Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy.

Kunhan Ni, Yixuan Huang, Simiao Lu, Longlin Jiang, Huan Zhang, Wenwu He, Chenghao Wang, Qiang Zhou, Haojun Li, Jialong Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kunhan NiDepartment of Thoracic Surgery, the Affiliated Hospital of Southwest Medical University, Sichuan, Luzhou, China.
Yixuan HuangDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Simiao LuDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Longlin JiangDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Huan ZhangDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Wenwu HeDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Chenghao WangDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Qiang ZhouDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Haojun LiDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Jialong LiDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Kangning WangDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Guangyuan LiuDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Qiang FangDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Lin PengDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Xuefeng LengDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Yongtao HanDepartment of Thoracic Surgery, the Affiliated Hospital of Southwest Medical University, Sichuan, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To compare the recurrence patterns and survival outcomes between patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (NCRT) and adjuvant chemoradiotherapy (ACRT). Methods: We retrospectively analyzed 267 patients with locally advanced ESCC who received treatment at Sichuan Cancer Hospital and Institute (Chengdu, China) between January 2018 and December 2020. Based on different treatment protocols, the patients were divided into two groups: NCRT (n=181) and ACRT (n=86). After propensity score matching, each group included 74 patients. This study compared the recurrence types, sites, frequencies, and timing, as well as overall survival (OS), disease-free survival (DFS), and prognostic risk factors between the two groups. Results: The recurrence rates in the NCRT and ACRT groups were 59.5% (44/74) and 33.8% (25/74), respectively; the difference was statistically significant (P=0.002). Recurrences primarily occurred within 2 years following esophagectomy. The ACRT group had a higher 3-year OS rate than the NCRT group (67.8% versus [vs.] 50.6%, respectively; P=0.019). In the subgroup of patients with local recurrence, the 3-year OS rate was higher in the NCRT group compared to the ACRT group (53.8% vs. 0%, respectively; P=0.029). In terms of DFS, the ACRT group exhibited better results than the NCRT group (P<0.001). Multivariate analysis revealed that pathological N staging was an independent risk factor affecting the OS prognosis of patients in the NCRT group. Margin status and pathological T staging were identified as independent risk factors influencing OS in the ACRT group, while sex and treatment regimen were independent risk factors affecting DFS in patients with postoperative pathological lymph node positivity. Conclusion: There was significant difference in the OS and DFS prognosis of patients with ESCC treated with NCRT and ACRT. Recurrence primarily occurs within 2 years following esophagectomy. The recurrence rate was higher in the NCRT group compared to the ACRT group. Patients with early recurrence had a poorer survival prognosis compared to those with late recurrence. Pathological N staging was identified as an independent risk factor affecting OS in the NCRT group. Furthermore, margin status and pathological T staging were independent risk factors influencing OS in the ACRT group.

Indexed as

chemoradiotherapyesophageal squamous cell carcinomaesophagectomypropensity score matchingrecurrence patterns

Identifiers

PMID40589636
PMCPMC12206882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.